{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:07:53Z","timestamp":1789952873141,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40263-015-0258-7","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T10:20:41Z","timestamp":1436869241000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["[18F]Florbetaben: A Review in \u03b2-Amyloid PET Imaging in Cognitive Impairment"],"prefix":"10.1007","volume":"29","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"issue":"5580","key":"258_CR1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science."},{"issue":"6","key":"258_CR2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol."},{"issue":"3","key":"258_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):257\u201362.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"258_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1155\/2009\/609839","volume":"21","author":"GD Rabinovici","year":"2009","unstructured":"Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1):117\u201328.","journal-title":"Behav Neurol."},{"issue":"11","key":"258_CR5","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.110.076315","volume":"52","author":"CC Rowe","year":"2011","unstructured":"Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52(11):1733\u201340.","journal-title":"J Nucl Med."},{"issue":"3","key":"258_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319.","journal-title":"Ann Neurol."},{"issue":"6","key":"258_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","volume":"42","author":"CA Mathis","year":"2012","unstructured":"Mathis CA, Mason NS, Lopresti BJ, et al. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med. 2012;42(6):423\u201332.","journal-title":"Semin Nucl Med."},{"issue":"2","key":"258_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129\u201335.","journal-title":"Lancet Neurol."},{"issue":"8","key":"258_CR9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","volume":"32","author":"W Zhang","year":"2005","unstructured":"Zhang W, Oya S, Kung MP, et al. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting A\u03b2 aggregates in the brain. Nucl Med Biol. 2005;32(8):799\u2013809.","journal-title":"Nucl Med Biol."},{"key":"258_CR10","unstructured":"European Medicines Agency. Neuraceq 300\u00a0MBq\/mL solution for injection: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu . Accessed 13 Mar 2015."},{"issue":"1","key":"258_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, et al. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3(1):13\u201326.","journal-title":"Clin Transl Imaging."},{"issue":"7","key":"258_CR12","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/brain\/awt142","volume":"136","author":"R Ni","year":"2013","unstructured":"Ni R, Gillberg PG, Bergfors A, et al. Amyloid tracers detect multiple binding sites in Alzheimer\u2019s disease brain tissue. Brain. 2013;136(7):2217\u201327.","journal-title":"Brain."},{"issue":"7","key":"258_CR13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.nucmedbio.2012.03.001","volume":"39","author":"MT Fodero-Tavoletti","year":"2012","unstructured":"Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, et al. In vitro characterization of [18F]-florbetaben, an A\u03b2 imaging radiotracer. Nucl Med Biol. 2012;39(7):1042\u20138.","journal-title":"Nucl Med Biol."},{"key":"258_CR14","unstructured":"Piramal Imaging. Neuraceq (florbetaben F 18 injection): US prescribing information. 2014. http:\/\/www.neuraceq.com . Accessed 13 Mar 2015."},{"issue":"7","key":"258_CR15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2967\/jnumed.112.114660","volume":"54","author":"A Rominger","year":"2013","unstructured":"Rominger A, Brendel M, Burgold S, et al. Longitudinal assessment of cerebral \u03b2-amyloid deposition in mice overexpressing Swedish mutant \u03b2-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54(7):1127\u201334.","journal-title":"J Nucl Med."},{"key":"258_CR16","author":"M Brendel","year":"2015","unstructured":"Brendel M, Jaworska A, Herms J, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. Mol Psychiatry. 2015;. doi: 10.1038\/mp.2015.74 .","journal-title":"Mol Psychiatry."},{"key":"258_CR17","unstructured":"European Medicines Agency. Neuraceq [florbetaben (18F)]: assessment report for an initial marketing authorisation application. 2013. http:\/\/www.ema.europa.eu . Accessed 13 Mar 2015."},{"issue":"1","key":"258_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00259-014-2890-8","volume":"42","author":"M Senda","year":"2015","unstructured":"Senda M, Sasaki M, Yamane T, et al. Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. Eur J Nucl Med Mol Imaging. 2015;42(1):89\u201396.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"258_CR19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10967-010-0514-8","volume":"284","author":"M Patt","year":"2010","unstructured":"Patt M, Schildan A, Barthel H, et al. Metabolite analysis of [18F]florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanal Nucl Chem. 2010;284(3):557\u201362.","journal-title":"J Radioanal Nucl Chem."},{"issue":"8","key":"258_CR20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210\u20137.","journal-title":"J Nucl Med."},{"issue":"9","key":"258_CR21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","volume":"38","author":"H Barthel","year":"2011","unstructured":"Barthel H, Luthardt J, Becker G, et al. Individualized quantification of brain \u03b2-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer\u2019s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38(9):1702\u201314.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"258_CR22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335.","journal-title":"Lancet Neurol."},{"key":"258_CR23","unstructured":"Sabri O, Seibyl J, Ishihara K, et al. Close to clinical routine phase 2 trial on florbetaben PET imaging of \u03b2-amyloid (A\u03b2) in Alzheimer\u2019s disease (AD) [abstract no. 299]. J Nucl Med. 2013;54(Suppl 2)."},{"issue":"6","key":"258_CR24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","volume":"39","author":"VL Villemagne","year":"2012","unstructured":"Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for A\u03b2 imaging in ageing and Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983\u20139.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"258_CR25","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2014. http:\/\/www.clinicaltrials.gov\/ . Accessed 13 Mar 2015."},{"issue":"5","key":"258_CR26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000001212","volume":"84","author":"D Jennings","year":"2015","unstructured":"Jennings D, Seibyl J, Sabbagh M, et al. Age dependence of brain \u03b2-amyloid deposition in Down syndrome: an [18F]florbetaben PET study. Neurology. 2015;84(5):500\u20137.","journal-title":"Neurology."},{"issue":"4","key":"258_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","volume":"86","author":"KT Ong","year":"2015","unstructured":"Ong KT, Villemagne VL, Bahar-Fuchs A, et al. A\u03b2 imaging with 18F-florbetaben in prodromal Alzheimer\u2019s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86(4):431\u20136.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"258_CR28","unstructured":"US Food and Drug Administration. Neuraceq (florbetaben F 18 injection): clinical pharmacology and biopharmaceutics review(s). 2014. http:\/\/www.fda.gov\/ . Accessed 13 Mar 2015."},{"issue":"Suppl 2","key":"258_CR29","first-page":"S274","volume":"37","author":"B Sattler","year":"2010","unstructured":"Sattler B, Barthel H, Patt M, et al. Radiation exposure by [F18]florbetaben, a new PET tracer for detection of cerebral \u03b2-amyloid in Caucasian and Asian healthy volunteers [abstract no. OP432]. Eur J Nucl Med Mol Imaging. 2010;37(Suppl 2):S274.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"258_CR30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2967\/jnumed.108.055756","volume":"50","author":"GJ O\u2019Keefe","year":"2009","unstructured":"O\u2019Keefe GJ, Saunder TH, Ng S, et al. Radiation dosimetry of \u03b2-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med. 2009;50(2):309\u201315.","journal-title":"J Nucl Med."},{"key":"258_CR31","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015. doi: 10.1016\/j.jalz.2015.02.004 .","journal-title":"Alzheimers Dement."},{"key":"258_CR32","unstructured":"Seibyl J, Barthel H, Stephens A, et al. Reliability, reproducibility and efficacy of the 18F florbetaben \u03b2-amyloid PET scan visual assessment method as trained via a computer-based instructional tool [abstract no. 300]. J Nucl Med. 2013;54(Suppl 2)."},{"key":"258_CR33","unstructured":"Piramal Imaging SA. Piramal Imaging SA and Ci-Co Healthcare announce commercial approval of Neuraceq\u2122 in Korea [media release]. 2 Jun 2015. http:\/\/www.piramal.com ."},{"issue":"3","key":"258_CR34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"258_CR35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"258_CR36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement."},{"key":"258_CR37","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Neurocognitive disorders. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"258_CR38","doi-asserted-by":"crossref","unstructured":"Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. Alzheimers Dement. 2013;9(1):e-1\u201316.","DOI":"10.1016\/j.jalz.2013.01.002"},{"issue":"6","key":"258_CR39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000339367","volume":"33","author":"CG Schipke","year":"2012","unstructured":"Schipke CG, Peters O, Heuser I, et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2012;33(6):416\u201322.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"7","key":"258_CR40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12603-014-0507-3","volume":"18","author":"P Saidlitz","year":"2014","unstructured":"Saidlitz P, Voisin T, Vellas B, et al. Amyloid imaging in Alzheimer\u2019s disease: a literature review. J Nutr Health Aging. 2014;18(7):723\u201340.","journal-title":"J Nutr Health Aging."},{"key":"258_CR41","doi-asserted-by":"crossref","unstructured":"Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315 e1\u20134.","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"258_CR42","unstructured":"Data on file, Piramal Imaging. 2015."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0258-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0258-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T01:42:14Z","timestamp":1652838134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0258-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}